A Comparison of the Ocular Hypotensive Efficacy of Once-daily and Twice-daily Levobunolol Treatment

Sanford I. Rakofsky, Shlomo Melamed, John S. Cohen, J. Rigby Slight, George Spaeth, Richard A. Lewis, Lilly Zbrowski-Gutman, Cheryl Y. Eto, John C. Lue, Gary D. Novack

Research output: Contribution to journalArticlepeer-review

Abstract

The authors compared the ocular hypotensive efficacy of two different treatment regimens of levobunolol 0.5% in a double-masked, randomized, controlled clinical trial. Seventy-one patients with open-angle glaucoma or ocular hypertension received levobunolol 0.5% as their sole glaucoma medication either on a once-daily or twice-daily treatment regimen for 3 months. Approximately 81 % of the patients in the once-daily treatment group and 88% of subjects in the twice-daily treatment group successfully completed the 3-month study period. The overall mean decrease in intraocular pressure (10P) was 4.5 mmHg in the once-daily group and 5.6 mmHg in the twice-daily group. These differences were not statistically different. For both treatment groups, effects on mean heart rate and blood pressure were minimal. The authors' data from this population suggest that once-daily treatment with levobunolol is an effective glaucoma regimen.

Original languageEnglish
Pages (from-to)8-11
Number of pages4
JournalOphthalmology
Volume96
Issue number1
DOIs
StatePublished - 1989
Externally publishedYes

Fingerprint

Dive into the research topics of 'A Comparison of the Ocular Hypotensive Efficacy of Once-daily and Twice-daily Levobunolol Treatment'. Together they form a unique fingerprint.

Cite this